Vanguard Group
APRE icon

Vanguard Group’s Aprea Therapeutics APRE Stock Holding History

Vanguard Group’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$49.5K Sell
58,086
-100,152
-63% -$123K ﹤0.01% 4248
2025
Q3 		$233K Sell
158,238
-15,604
-9% -$25.7K ﹤0.01% 4103
2025
Q2 		$296K Hold
173,842
– – ﹤0.01% 4027
2025
Q1 		$355K Hold
173,842
– – ﹤0.01% 3961
2024
Q4 		$570K Hold
173,842
– – ﹤0.01% 3915
2024
Q3 		$478K Buy
173,842
+58,004
+50% +$205K ﹤0.01% 3981
2024
Q2 		$471K Sell
115,838
-140
-0.1% -$722 ﹤0.01% 4027
2024
Q1 		$776K Buy
115,978
+81,290
+234% +$505K ﹤0.01% 3892
2023
Q4 		$163K Buy
34,688
+7,347
+27% +$30.1K ﹤0.01% 4249
2023
Q3 		$114K Buy
27,341
+11,840
+76% +$43.2K ﹤0.01% 4334
2023
Q2 		$48.8K Hold
15,501
– – ﹤0.01% 4459
2023
Q1 		$68.8K Hold
15,501
– – ﹤0.01% 4437
2022
Q4 		$103K Buy
15,501
+21
+0.1% +$222 ﹤0.01% 4392
2022
Q3 		$201K Sell
15,480
-2,295
-13% -$40.7K ﹤0.01% 4415
2022
Q2 		$266K Hold
17,775
– – ﹤0.01% 4428
2022
Q1 		$662K Sell
17,775
-17,066
-49% -$699K ﹤0.01% 4327
2021
Q4 		$2M Sell
34,841
-1,030
-3% -$91K ﹤0.01% 4039
2021
Q3 		$3.67M Buy
35,871
+500
+1% +$45.4K ﹤0.01% 3827
2021
Q2 		$3.45M Sell
35,371
-2,266
-6% -$209K ﹤0.01% 3772
2021
Q1 		$3.84M Buy
37,637
+151
+0.4% +$17.6K ﹤0.01% 3662
2020
Q4 		$3.69M Buy
37,486
+5,326
+17% +$2.53M ﹤0.01% 3488
2020
Q3 		$15.5M Buy
32,160
+1,941
+6% +$1.09M ﹤0.01% 2575
2020
Q2 		$23.4M Buy
30,219
+16,796
+125% +$11M ﹤0.01% 2346
2020
Q1 		$9.33M Buy
13,423
+323
+2% +$237K ﹤0.01% 2654
2019
Q4 		$12M Buy
+13,100
New +$7.21M ﹤0.01% 2771

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Vanguard Group's APRE Position: Q4 2025 in Review

Vanguard Group reduced its Aprea Therapeutics (APRE) stake by 63% in Q4 2025, selling an estimated $123K and leaving 58,086 shares worth $49.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4248.

Vanguard Group first reported a position in APRE in Q4 2019 and has held it in 25 quarters since. The position peaked at $23.4M in Q2 2020. 22 funds tracked by Wall St. Rank hold APRE as of Q4 2025.

  • Vanguard Group held 58,086 shares of Aprea Therapeutics worth $49.5K as of Q4 2025.
  • Vanguard Group sold 100,152 Aprea Therapeutics shares in Q4 2025, an estimated $123K.
  • Aprea Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4248 holding.
  • Vanguard Group first reported a position in Aprea Therapeutics in Q4 2019 and has held it in 25 quarters since.
  • Vanguard Group's Aprea Therapeutics position peaked at $23.4M in Q2 2020.
  • 22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.